Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Baucus Comparative Effectiveness Bill Flirts With Cost Effectiveness Issue

Executive Summary

Legislation aimed at the development of a private, nonprofit corporation to drive comparative effectiveness research tentatively ventures into the realm of comparing the cost effectiveness of medical treatments

You may also be interested in...



Baucus to Proceed With Public/Private Comparative Effectiveness Vision

Even with the inclusion of comparative effectiveness research funding in the American Recovery and Reinvestment Act, Senate Finance Committee Chairman Max Baucus is showing no signs of abandoning plans to include comparative effectiveness in the upcoming health care reform debate

Baucus to Proceed With Public/Private Comparative Effectiveness Vision

Even with the inclusion of comparative effectiveness research funding in the American Recovery and Reinvestment Act, Senate Finance Committee Chairman Max Baucus is showing no signs of abandoning plans to include comparative effectiveness in the upcoming health care reform debate

PhRMA, BIO Alliance Promotes Industry Agenda On Comparative Effectiveness

The Pharmaceutical Research and Manufacturers of America, the Biotechnology Industry Organization and the Advanced Medical Technology Association have formed a coalition to promote an industry agenda on comparative clinical effectiveness

Latest News
See All
UsernamePublicRestriction

Register

PS049984

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel